Insider Transactions in Q1 2023 at Eli Lilly & CO (LLY)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
205,000
-0.07%
|
$70,110,000
$342.71 P/Share
|
|
Mar 24
2023
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
200,000
-0.1%
|
$67,200,000
$336.18 P/Share
|
|
Mar 20
2023
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
43
+0.29%
|
$14,319
$333.6 P/Share
|
|
Mar 20
2023
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.91%
|
$4,995
$333.6 P/Share
|
|
Mar 20
2023
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.01%
|
$1,998
$333.6 P/Share
|
|
Mar 20
2023
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+4.38%
|
$9,990
$333.6 P/Share
|
|
Mar 20
2023
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
29
+1.4%
|
$9,657
$333.6 P/Share
|
|
Mar 20
2023
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
34
+0.06%
|
$11,322
$333.6 P/Share
|
|
Mar 20
2023
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+0.04%
|
$9,990
$333.6 P/Share
|
|
Mar 10
2023
|
Alonzo Weems EVP, ERM & CECO |
SELL
Open market or private sale
|
Direct |
1,000
-10.09%
|
$318,000
$318.85 P/Share
|
|
Mar 01
2023
|
Alonzo Weems EVP, ERM & CECO |
SELL
Payment of exercise price or tax liability
|
Direct |
793
-7.41%
|
$246,623
$311.22 P/Share
|
|
Mar 01
2023
|
Alonzo Weems EVP, ERM & CECO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,779
+14.25%
|
-
|
|
Mar 01
2023
|
Eric Dozier EVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
714
-9.49%
|
$222,054
$311.22 P/Share
|
|
Mar 01
2023
|
Eric Dozier EVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
1,602
+17.56%
|
-
|
|
Mar 01
2023
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
843
-3.04%
|
$262,173
$311.22 P/Share
|
|
Mar 01
2023
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,890
+6.39%
|
-
|
|
Feb 27
2023
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
600
-8.36%
|
$193,200
$322.47 P/Share
|
|
Feb 21
2023
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
44
+0.3%
|
$14,388
$327.51 P/Share
|
|
Feb 21
2023
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+1.47%
|
$9,810
$327.51 P/Share
|
|
Feb 21
2023
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.92%
|
$4,905
$327.51 P/Share
|
|
Feb 21
2023
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+4.59%
|
$9,810
$327.51 P/Share
|
|
Feb 21
2023
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.07%
|
$11,445
$327.51 P/Share
|
|
Feb 21
2023
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
30
+0.04%
|
$9,810
$327.51 P/Share
|
|
Feb 21
2023
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.01%
|
$1,962
$327.51 P/Share
|
|
Feb 17
2023
|
Johna Norton EVP, Global Quality |
SELL
Bona fide gift
|
Direct |
500
-1.47%
|
-
|
|
Feb 16
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-9.99%
|
$440,190
$335.01 P/Share
|
|
Feb 16
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
2,785
+17.47%
|
-
|
|
Feb 13
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Open market or private sale
|
Direct |
2,500
-4.14%
|
$865,000
$346.47 P/Share
|
|
Feb 10
2023
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
1,350
+9.42%
|
$465,750
$345.12 P/Share
|
|
Feb 10
2023
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,904
+20.96%
|
$656,880
$345.12 P/Share
|
|
Feb 10
2023
|
Alonzo Weems EVP, ERM & CECO |
BUY
Grant, award, or other acquisition
|
Direct |
2,422
+21.35%
|
$835,590
$345.12 P/Share
|
|
Feb 10
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Open market or private sale
|
Direct |
2,500
-3.97%
|
$855,000
$342.76 P/Share
|
|
Feb 10
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
8,562
+11.98%
|
$2,953,890
$345.12 P/Share
|
|
Feb 10
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
18,388
+14.83%
|
$6,343,860
$345.12 P/Share
|
|
Feb 10
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
2,407
+18.83%
|
$830,415
$345.12 P/Share
|
|
Feb 10
2023
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
56,208
+11.24%
|
$19,391,760
$345.12 P/Share
|
|
Feb 10
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Grant, award, or other acquisition
|
Direct |
8,023
+16.96%
|
$2,767,935
$345.12 P/Share
|
|
Feb 10
2023
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
2,507
+6.88%
|
$864,915
$345.12 P/Share
|
|
Feb 10
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Grant, award, or other acquisition
|
Direct |
3,681
+10.42%
|
$1,269,945
$345.12 P/Share
|
|
Feb 10
2023
|
Patrik Jonsson EVP&Pres, LLY Dia&Obe, LLY USA |
BUY
Grant, award, or other acquisition
|
Direct |
7,886
+15.52%
|
$2,720,670
$345.12 P/Share
|
|
Feb 10
2023
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,204
+16.78%
|
$1,795,380
$345.12 P/Share
|
|
Feb 10
2023
|
Anat Ashkenazi EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+14.94%
|
$2,309,085
$345.12 P/Share
|
|
Feb 10
2023
|
Eric Dozier EVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
1,820
+23.51%
|
$627,900
$345.12 P/Share
|
|
Feb 10
2023
|
Anat Hakim EVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
9,072
+29.02%
|
$3,129,840
$345.12 P/Share
|
|
Feb 08
2023
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
4,200
-1.07%
|
-
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
7,035
-7.47%
|
$2,420,040
$344.15 P/Share
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
15,675
+14.26%
|
-
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
3,252
-5.64%
|
$1,118,688
$344.15 P/Share
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
7,264
+11.2%
|
-
|
|
Feb 01
2023
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
941
-2.91%
|
$323,704
$344.15 P/Share
|